MORE....according to an Associated Press article released earlier this month. The recommendation stems from the availability of sophisticated new treatments including stereotactic radiosurgeryfor metastatic brain tumors that are detected early.
Neurologists from the Chicago Institute of Neurosurgery and Neuroresearch (CINN) and the University of Pittsburgh Cancer Center explained that cancer patients are surviving longer, which increases the risk of metastatic brain tumors. Up to 40 percent of lung cancer patients and 33 percent of breast cancer patients develop these tumors. Patients with melanoma, kidney cancer, and colon cancer are also at risk. Routine brain scans can detect these tumors, which can be treated with drugs as well as stereotactic radiosurgery.
Among the sophisticated radiosurgery treatment options for patients at CINN is Gamma Knife(R) surgery. There is also a Leksell Gamma Knife(R) at the University of Pittsburgh Medical Center. Overall, Leksell Gamma Knife(R) is installed at more than 100 facilities in the U.S. (for center locations, visit http://www.elekta.com). Leksell Gamma Knife(R) from Elekta remains the solution of choice and the standard of care for intracranial stereotactic radiosurgery.
'The combination of early detection and Gamma Knife(R) surgery provides one of the best possible outcomes for patients who are treated via stereotactic radiosurgery,' says Jim Rose, VP Marketing, North America. 'It also offers the gentlest care. Because the procedure is wholly noninvasive, patients often go home the same day they receive treatment.'
Often referred to as 'the gold standard' for radiosurgery, the Leksell Gamma Knife(R) from Elekta is the standard of care for neurosurgery, with thousands of published papers on treatment efficacy and improved quality of life for patients.
Gamma Knife(R) surgery is a noninvasive method for treating targets in the brain. It delivers a single, high dose of irradiation to the precisely located target, without harming the surrounding healthy tissue."